No Data
No Data
Xinguang Pharmaceutical: 2024 Semi-Annual Report
Xinguang Pharmaceutical: 2024 Semi-Annual Report Summary
Zhejiang Xinguang Pharmaceutical (300519.SZ) released its half-year performance, with a net income of 25.5077 million yuan, a decrease of 33.81%.
Zhejiang Xinguang Pharmaceutical (300519.SZ) released its 2024 interim report, with a revenue of 0.146 billion...
Zhejiang Xinguang Pharmaceutical (300519.SZ): The net income in the first half of the year was 25.5077 million yuan, a year-on-year decrease of 33.81%.
On August 26th, Xinguang Pharmaceutical (300519.SZ) released its semi-annual report for 2024, with a total operating income of 0.146 billion yuan for the reporting period, a decrease of 1.90% year-on-year; net income attributable to shareholders of listed companies was 25.5077 million yuan, a decrease of 33.81% year-on-year; net income attributable to shareholders of listed companies after deducting non-recurring gains and losses was 22.5745 million yuan, a decrease of 36.83% year-on-year; basic earnings per share was 0.16 yuan.
Investor Optimism Abounds Zhejiang Xinguang Pharmaceutical Co., Ltd. (SZSE:300519) But Growth Is Lacking
Xinguang Pharmaceutical (300519.SZ) 2023 equity distribution: 4 yuan for every 10 shares
Xinguang Pharmaceutical (300519.SZ) issued an announcement. The company's 2023 equity distribution plan is: With the company's current...
No Data
No Data